MIIT Vigorously Promotes Innovative Development of AI-Driven Medical Devices

Release time:

2025-03-01

At the recently held China Medical Equipment Conference and the 27th Annual Symposium on Academic and Technological Exchange in Suzhou, Xin Guobin, Vice Minister of Industry and Information Technology, stated that the MIIT is working closely with relevant departments to vigorously promote the development of AI-powered medical equipment.

MIIT Vigorously Promotes Innovative Development of AI-Driven Medical Devices

Recently, at the China Medical Equipment Conference and the 27th Annual Symposium on Academic and Technological Exchange held in Suzhou, Xin Guobin, Vice Minister of Industry and Information Technology, stated that the MIIT is working closely with relevant departments to vigorously promote the development of AI-powered medical equipment.

　　Xin Guobin pointed out that the integration of advanced technologies with artificial intelligence will establish a strategic high ground for the future development of the healthcare sector, serving as a crucial direction for medical-device companies to drive innovation and reshape their value chains. Currently, under the combined influence of market dynamics and policy support, the medical-device industry is accelerating its transformation toward digitalization, precision, and intelligentization, with an increasing array of cutting-edge medical products deeply integrated with AI—such as electronic health-record systems, telemedicine platforms, high-end medical-imaging equipment, and surgical robots. The Ministry of Industry and Information Technology is working closely with relevant departments to strengthen top-level design, build a comprehensive policy framework, continuously consolidate the foundations for industrial development, guide enterprises in speeding up R&D of new products, and promote the application of AI technologies in the medical-device field. At the same time, the ministry is actively establishing collaborative platforms to facilitate closer alignment between supply and demand; last year, it supported 21 hospitals, including Beijing Jishuitan Hospital, in partnering with relevant enterprises to establish orthopedic-surgical-robot application centers, thereby exploring the development of technical standards and clinical-application guidelines. In addition, efforts are underway to foster coordinated collaboration between central and local authorities and to advance military–civilian integration, laying the groundwork for an emerging pattern of seamless integration between industry and end-users.

　　Xin Guobin also pointed out that China’s overall level of artificial intelligence technology still lags significantly behind that of developed countries. AI technology has the potential to serve as a strategic breakthrough for driving the future development of medical equipment; therefore, it is essential to strengthen innovation, expand applications, establish standards, and cultivate talent in order to facilitate the transformation and upgrading of enterprises—from merely keeping pace with others to running alongside and ultimately leading the way.

Related News

Overview of Bioanalytical Methods for Cell Therapy Products

Cell and gene therapy (CGT) can be broadly classified, based on product format, into ex vivo gene therapy and in vivo gene therapy.

2026-04-03

Bioanalytical Strategies for CGT Products: Selected Developments and Validation of qPCR/ddPCR Methodologies

With the rapid development of cell and gene therapy (CGT), dozens of CGT products have now been approved for market launch worldwide.

2026-04-03

Pharmaceutical and Biotechnology Industry Watch: Innovative Drugs and Medical Devices Fuel Structured Market Performance; AI in Healthcare Opens New Growth Opportunities

During the third week of February 2025, the pharmaceutical and biotechnology sector continued to exhibit structural divergence. Over the week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming both the CSI 300 Index and the Shanghai Composite Index, ranking ninth in terms of sector performance.

2025-03-01

Pharmaceutical and Biotechnology Industry Watch: AI-Driven Healthcare Applications Accelerate Deployment; Breakthroughs in Payment-Policy for Innovative Drugs

Recently, the pharmaceutical and biotechnology sector has exhibited a pronounced structural market trend, driven by the deep integration of AI technologies with healthcare applications, which is spurring industry upgrades. At the same time, policy support for innovative drugs continues to strengthen, creating multiple favorable factors for the sector.

2025-03-01

With the concerted support of 17 departments, the latest policies for the biopharmaceutical industry in the Jiangsu Pilot Free Trade Zone have been unveiled!

Recently, the “Policy Measures for Coordinated Support from Relevant Provincial Departments for the Open and Innovative Development of the Biopharmaceutical Industry in the China (Jiangsu) Pilot Free Trade Zone” (hereinafter referred to as the “Policy Measures”) were officially released!

2025-03-01

Medical Device Industry Development Report: Significant Market Potential in Countries Along the Belt and Road

Recently, the “Medical Device Blue Book: Report on the Development of China’s Medical Device Industry (2018),” jointly released in Beijing by the China Association for Pharmaceutical Regulatory Research and the Social Sciences Academic Press, stated that since the Belt and Road Initiative was proposed in 2013, demand for Chinese medical device products has increased among countries along the Belt and Road.

2025-03-01

Share